Microvast Holdings announces departure of chief financial officer
LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC), a company recognized for its expertise in the field of nicotinamide adenine dinucleotide (NAD+) and healthy aging, has announced that it will undergo a corporate rebranding. The company, which has delivered an impressive 273% return over the past year according to InvestingPro data, maintains a strong financial position with a healthy current ratio of 3.57. Starting Wednesday, March 19, 2025, the company will operate under the new name Niagen Bioscience, Inc. and will be trading on the Nasdaq stock market with a new ticker symbol, NAGE.
This change reflects the company’s commitment to its flagship ingredient, Niagen (nicotinamide riboside, or NR), which has been clinically proven to boost NAD+ levels. NAD+ is a vital coenzyme present in all human cells that decreases with age and stress, and its depletion is linked to age-related health changes. With revenue growth of 19% in the last twelve months and analysts maintaining a strong buy consensus, the company’s focus on this market appears well-positioned. For detailed analysis and additional insights, investors can access the comprehensive Pro Research Report available on InvestingPro.
The rebranding initiative is part of a broader strategy to align the company’s corporate identity more closely with its primary product and mission. ChromaDex has established itself as a leader in the science of healthy aging through its rigorous scientific research and product quality. Niagen, their leading consumer product sold under the brand Tru Niagen, has gained significant market presence as a top healthy-aging NAD+ supplement in the United States.
Existing shareholders will not need to take any action regarding the ticker symbol change, as the company’s common stock will continue to be listed on Nasdaq and the CUSIP number will remain the same.
ChromaDex has been at the forefront of NAD+ science, working with independent researchers globally to explore the full potential of this coenzyme. The company’s patent portfolio also protects NR and other NAD+ precursors, ensuring its position in the market. With a gross profit margin of 62% and operating with moderate debt levels, the company demonstrates strong financial fundamentals. InvestingPro analysis reveals 15 additional key insights about ChromaDex’s financial health and market position.
Further updates about the company’s rebranding and future plans are expected to follow. The information provided is based on a press release statement from ChromaDex Corp.
In other recent news, ChromaDex Corporation reported a strong financial performance for the fourth quarter of 2024, with earnings per share (EPS) reaching $0.09, significantly exceeding the forecasted $0.02. The company’s revenue for the quarter was $29.1 million, surpassing expectations of $26.78 million. ChromaDex’s flagship product, TRU NIAGEN, contributed $22.7 million to the revenue, which was key in achieving a 37% year-over-year increase in total net sales. The company ended the year with $99.6 million in full-year net revenues, marking a 19% growth compared to the previous year, and reported a net income of $7.2 million for the fourth quarter. Analyst firm H.C. Wainwright responded to these results by raising ChromaDex’s stock price target to $11 from $8, maintaining a Buy rating. The firm also adjusted its sales forecast for 2025 to $118 million, slightly down from a previous estimate, but introduced a new 2026 sales estimate of $145 million. ChromaDex’s financial health has improved with adjusted EBITDA rising to $3.4 million from $1.3 million year-over-year, and the company ended the year with $44.7 million in cash and no debt. The company projects an 18% revenue growth for 2025, with plans for continued investment in research and development and a potential corporate rebranding.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.